Inflammatory modulation of the response of bronchial epithelial cells to lipopolysaccharide with pretreatment by montelukast
Апстракт
Montelukast, a leukotriene receptor antagonist, is the most prescribed nonsteroidal anti-inflammatory drug used as an add-on therapy for asthma. Besides its effect on blocking leukotriene action, montelukast has been proposed to have secondary anti-inflammatory properties. This study aimed to investigate the modulatory effect of montelukast on the expression of major genes involved in airway inflammation (TNF, IL6) and remodeling (MMP9, TGFB1) in response to lipopolysaccharide (LPS) in vitro. The expression of selected genes was measured by quantitative real-time polymerase chain reaction 0h and 24h after LPS stimulation in cells pretreated with montelukast. Montelukast was found to significantly attenuate increased TNF and IL6 gene expression, to have a mild effect on MMP9 and have no effect on TGFB1 expression upon stimulation with LPS. The results of our study indicate that patients on montelukast therapy would have an adequate response to acute microorganism-induced inflammation, s...o additional anti-inflammatory effects of montelukast should be better exploited.
Кључне речи:
treatment / montelukast / inflammation / gene expression / asthmaИзвор:
Kragujevac Journal of Science, 2022, 44, 115-125Издавач:
- Univerzitet u Kragujevcu - Prirodno-matematički fakultet, Kragujevac
Финансирање / пројекти:
- Министарство науке, технолошког развоја и иновација Републике Србије, институционално финансирање - 200042 (Универзитет у Београду, Институт за молекуларну генетику и генетичко инжењерство) (RS-MESTD-inst-2020-200042)
Институција/група
Institut za molekularnu genetiku i genetičko inženjerstvoTY - JOUR AU - Jendrišek, Gorana AU - Nikolić, Aleksandra AU - Dragičević, Sandra PY - 2022 UR - https://imagine.imgge.bg.ac.rs/handle/123456789/1512 AB - Montelukast, a leukotriene receptor antagonist, is the most prescribed nonsteroidal anti-inflammatory drug used as an add-on therapy for asthma. Besides its effect on blocking leukotriene action, montelukast has been proposed to have secondary anti-inflammatory properties. This study aimed to investigate the modulatory effect of montelukast on the expression of major genes involved in airway inflammation (TNF, IL6) and remodeling (MMP9, TGFB1) in response to lipopolysaccharide (LPS) in vitro. The expression of selected genes was measured by quantitative real-time polymerase chain reaction 0h and 24h after LPS stimulation in cells pretreated with montelukast. Montelukast was found to significantly attenuate increased TNF and IL6 gene expression, to have a mild effect on MMP9 and have no effect on TGFB1 expression upon stimulation with LPS. The results of our study indicate that patients on montelukast therapy would have an adequate response to acute microorganism-induced inflammation, so additional anti-inflammatory effects of montelukast should be better exploited. PB - Univerzitet u Kragujevcu - Prirodno-matematički fakultet, Kragujevac T2 - Kragujevac Journal of Science T1 - Inflammatory modulation of the response of bronchial epithelial cells to lipopolysaccharide with pretreatment by montelukast EP - 125 IS - 44 SP - 115 DO - 10.5937/KgJSci2244115J ER -
@article{ author = "Jendrišek, Gorana and Nikolić, Aleksandra and Dragičević, Sandra", year = "2022", abstract = "Montelukast, a leukotriene receptor antagonist, is the most prescribed nonsteroidal anti-inflammatory drug used as an add-on therapy for asthma. Besides its effect on blocking leukotriene action, montelukast has been proposed to have secondary anti-inflammatory properties. This study aimed to investigate the modulatory effect of montelukast on the expression of major genes involved in airway inflammation (TNF, IL6) and remodeling (MMP9, TGFB1) in response to lipopolysaccharide (LPS) in vitro. The expression of selected genes was measured by quantitative real-time polymerase chain reaction 0h and 24h after LPS stimulation in cells pretreated with montelukast. Montelukast was found to significantly attenuate increased TNF and IL6 gene expression, to have a mild effect on MMP9 and have no effect on TGFB1 expression upon stimulation with LPS. The results of our study indicate that patients on montelukast therapy would have an adequate response to acute microorganism-induced inflammation, so additional anti-inflammatory effects of montelukast should be better exploited.", publisher = "Univerzitet u Kragujevcu - Prirodno-matematički fakultet, Kragujevac", journal = "Kragujevac Journal of Science", title = "Inflammatory modulation of the response of bronchial epithelial cells to lipopolysaccharide with pretreatment by montelukast", pages = "125-115", number = "44", doi = "10.5937/KgJSci2244115J" }
Jendrišek, G., Nikolić, A.,& Dragičević, S.. (2022). Inflammatory modulation of the response of bronchial epithelial cells to lipopolysaccharide with pretreatment by montelukast. in Kragujevac Journal of Science Univerzitet u Kragujevcu - Prirodno-matematički fakultet, Kragujevac.(44), 115-125. https://doi.org/10.5937/KgJSci2244115J
Jendrišek G, Nikolić A, Dragičević S. Inflammatory modulation of the response of bronchial epithelial cells to lipopolysaccharide with pretreatment by montelukast. in Kragujevac Journal of Science. 2022;(44):115-125. doi:10.5937/KgJSci2244115J .
Jendrišek, Gorana, Nikolić, Aleksandra, Dragičević, Sandra, "Inflammatory modulation of the response of bronchial epithelial cells to lipopolysaccharide with pretreatment by montelukast" in Kragujevac Journal of Science, no. 44 (2022):115-125, https://doi.org/10.5937/KgJSci2244115J . .